Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds SVB Leerink Downgrades AVEO Pharmaceuticals to Market Perform

SVB Leerink Downgrades AVEO Pharmaceuticals to Market Perform

SVB Leerink analyst Andrew Berens downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Outperform to Market Perform.

byBenzinga Newsdesk

October 24, 2022

1 minute read

SVB Leerink analyst Andrew Berens downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) from Outperform to Market Perform.

Jim Cramer Says Nvidia ‘Can And Will Prosper Without China’ Amid Successful Q3 Results: ‘Just Easier With Than Without’

By Benzinga Neuro

November 22, 1:49 AM

The restriction on Chinese imports by the U.S. government could affect Nvidia's future performance.

NVDA

Seattle Genetics Q2 EPS $(0.73) Beats $(0.86) Estimate, Sales $431.70M Miss $437.55M Estimate

By Michael Horton

July 28, 4:03 PM

Seattle Genetics (NASDAQ:SGEN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.86) by 15.12 percent. This is a 55.32 percent decrease over losses of $(0.47) per share from

SGEN

Analyst Ratings

Analyst Ratings for Fluence Energy

By Benzinga Insights

April 17, 2:00 PM

Over the past 3 months, 10 analysts have published their opinion on Fluence Energy (NASDAQ:FLNC) stock. These analysts…

FLNC

What’s Going On With Union Pacific Shares Today

By Akanksha Bakshi

July 26, 10:14 AM

Union Pacific Corp (NYSE: UNP) reported

UNP

SVB Leerink Downgrades AVEO Pharmaceuticals to Market Perform

Related Posts

Jim Cramer Says Nvidia ‘Can And Will Prosper Without China’ Amid Successful Q3 Results: ‘Just Easier With Than Without’

Seattle Genetics Q2 EPS $(0.73) Beats $(0.86) Estimate, Sales $431.70M Miss $437.55M Estimate

Analyst Ratings for Fluence Energy

What’s Going On With Union Pacific Shares Today